John Koo
YOU?
Author Swipe
View article: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria Open
ClinicalTrials.gov: NCT02260986, NCT04183335/NCT04202679, NCT04180488.
View article: Designing chatbots that can be trusted for patients with delusional infestation in the age of artificial intelligence
Designing chatbots that can be trusted for patients with delusional infestation in the age of artificial intelligence Open
This Perspectives article explores the ethical and clinical implications of integrating artificial intelligence (AI) chatbots into psychodermatology, focusing on patients with delusional infestation. We raise the central ethical question o…
View article: A 3-Dimensional Facial Analysis of Nasal Geometry Across Ethnicity, Sex, and Nasal Implants
A 3-Dimensional Facial Analysis of Nasal Geometry Across Ethnicity, Sex, and Nasal Implants Open
Summary: Mixed heritage faces have long been celebrated for their beauty, but there is limited data on the nasal characteristics of these faces. We aim to quantitatively compare nasal geometry across ethnicities and sexes to test the hypot…
View article: Brodalumab: Seven-Year US Pharmacovigilance Report
Brodalumab: Seven-Year US Pharmacovigilance Report Open
The 7-year pharmacovigilance dataset reinforces the safety profile of brodalumab previously established through clinical trials and earlier pharmacovigilance reports, with no completed suicides and a low fungal infection rate.
View article: Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study
Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study Open
View article: Skin picking in Down syndrome: a patient speaks out
Skin picking in Down syndrome: a patient speaks out Open
Coping mechanisms are underexplored in people with Down syndrome, even though these individuals experience a higher prevalence of anxiety disorders, particularly obsessive–compulsive spectrum disorders. This article explores the perspectiv…
View article: Genital Psoriasis: Shining Light on This Hidden Disease
Genital Psoriasis: Shining Light on This Hidden Disease Open
Background Psoriasis occurring on the skin of the genital and perigenital regions, including the inguinal creases, vulva, penis, scrotum, perianal area, and the intergluteal cleft, has specific diagnostic and treatment requirements due to …
View article: CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study Open
ClinicalTrials.gov: NCT05495568.
View article: Claudin 18.2 expression profile in primary tumors and their ovarian metastases: implications for targeted therapy
Claudin 18.2 expression profile in primary tumors and their ovarian metastases: implications for targeted therapy Open
View article: Can pimozide kill parasites? Surprisingly, the most honest answer is ‘yes’
Can pimozide kill parasites? Surprisingly, the most honest answer is ‘yes’ Open
Conclusion: With adequate disclaimers that pimozide's therapeutic efficacy may not have to do with its anti-pathogen profile, the evidence that pimozide has anti-pathogenic properties may enable dermatology providers to strengthen t…
View article: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study Open
View article: Brodalumab: Six-Year US Pharmacovigilance Report
Brodalumab: Six-Year US Pharmacovigilance Report Open
View article: Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis
Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis Open
OBJECTIVE: Tildrakizumab, an anti–interleukin-23 p19 monoclonal antibody, is approved for the treatment of adults with moderate-to-severe plaque psoriasis. Limited evidence is available regarding the effects of tildrakizumab on patient-rep…
View article: Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting
Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting Open
Tildrakizumab improved long-term HRQoL in patients with psoriasis in a real-world setting.
View article: Brodalumab: 5-Year US Pharmacovigilance Report
Brodalumab: 5-Year US Pharmacovigilance Report Open
View article: Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis
Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis Open
ClinicalTrials.gov identifier, NCT03718299.
View article: Gene Expression Differences Identified in Skin Samples of Mycosis Fungoides, Atopic Dermatitis, and Psoriasis
Gene Expression Differences Identified in Skin Samples of Mycosis Fungoides, Atopic Dermatitis, and Psoriasis Open
Background: Recent advances in the understanding of the molecular mechanisms underlying atopic dermatitis (AD) and psoriasis (PSO) have led to the development of multiple targeted therapies. Yet, molecular heterogeneity contributes to inco…
View article: Pimozide-induced tardive dyskinesia in the treatment of delusions of infestation
Pimozide-induced tardive dyskinesia in the treatment of delusions of infestation Open
View article: When Should Dermatologists Refer Delusions of Parasitosis Patients to Psychiatry: An Expert Recommendation
When Should Dermatologists Refer Delusions of Parasitosis Patients to Psychiatry: An Expert Recommendation Open
Many patients with delusions of parasitosis (DoP) prefer to be managed by dermatologists rather than mental health professionals (MHPs). While some patients with DoP can be managed by dermatologists, others must be referred to MHPs. The pu…
View article: Gene Expression Differences Identified in Skin Samples of Early-Stage Mycosis Fungoides, Atopic Dermatitis, and Psoriasis
Gene Expression Differences Identified in Skin Samples of Early-Stage Mycosis Fungoides, Atopic Dermatitis, and Psoriasis Open
Methods• Robust gene expression is obtained from lesional PSO, AD, and MF samples collected by non-invasive skin scraping.• Gene expression differences are observed between PSO, AD, and MF lesions.• AD lesions from super-responders to dupi…
View article: Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation
Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation Open
View article: National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicine
National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicine Open
Telemedicine emerged as an alternative care delivery system used to offer effective long-term management to patients with chronic, inflammatory conditions such as psoriatic disease. Teledermatology can provide reliable clinical information…
View article: Brodalumab: 4-Year US Pharmacovigilance Report
Brodalumab: 4-Year US Pharmacovigilance Report Open
Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis in adults without response or with loss of response to other systemic therapies. Brodalumab carries a boxed warning in the Uni…
View article: Comparing the odds of reported depression in psoriasis patients on systemic therapy: a cross-sectional analysis of postmarketing data
Comparing the odds of reported depression in psoriasis patients on systemic therapy: a cross-sectional analysis of postmarketing data Open
Patients with psoriasis are more likely to experience depression and suicidality compared to non-psoriatic patients, though systemic therapies have been shown to improve depressive symptoms. It is unclear whether or not biologic or oral ag…
View article: Evolving Concepts in Psoriasis: Special Considerations for Patients With Skin of Color, Skin Barrier Dysfunction, and the Role of Adjunctive Skin Care
Evolving Concepts in Psoriasis: Special Considerations for Patients With Skin of Color, Skin Barrier Dysfunction, and the Role of Adjunctive Skin Care Open
Further study is needed to understand racial/ethnic population variations in psoriasis and develop strategies to reduce disparities in care. Addressing alterations in skin barrier function observed in psoriasis may help to improve treatmen…
View article: Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: A cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS)
Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: A cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) Open
To the Editor: Biologics are highly efficacious biologic for treating moderate-to-severe plaque psoriasis, particularly brodalumab.1Armstrong A.W. Soliman A.M. Betts K.A. et al.Comparative efficacy and relative ranking of biologics and ora…
View article: Management of delusions of parasitosis: an interview with experts in psychodermatology
Management of delusions of parasitosis: an interview with experts in psychodermatology Open
Delusions of parasitosis (DOP), which is also called Morgellons disease or delusional infestation, can be one of the most challenging clinical encounters in a dermatologist’s practice. One reason for this is lack of education during dermat…
View article: Contrasting between Atopic Dermatitis and Psoriasis in the Quality of Life Impact and the Prevalence of Psychiatric Disorders
Contrasting between Atopic Dermatitis and Psoriasis in the Quality of Life Impact and the Prevalence of Psychiatric Disorders Open
As chronic inflammatory skin conditions, psoriasis and atopic dermatitis have both been associated with significant psychosocial comorbidities. However, the similarities and differences between the two in the manifestation of psychologic/p…
View article: Onset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies
Onset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies Open
Brodalumab induces a rapid treatment response in patients with moderate-to-severe psoriasis and may promote earlier improvements in quality of life. J Drugs Dermatol. 2022;21(8):854-860. doi:10.36849/JDD.6791.
View article: Improving Access to Care for Patients with Psoriasis and Psoriatic Arthritis: The Impact of the Temporary Reciprocity to Ensure Access to Treatment Act and Remote Care Policy Reform
Improving Access to Care for Patients with Psoriasis and Psoriatic Arthritis: The Impact of the Temporary Reciprocity to Ensure Access to Treatment Act and Remote Care Policy Reform Open